SARC003: Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
PI: Elizabeth Fox, MD and Shreyas Patel, MD
Date Initiated: 5/05/2005
SARC003 on www.ClinicalTrials.gov
SARC004: Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
PI: Scott Schuetze, MD, PhD
Date Initiated: 4/21/2005
SARC004 on www.ClinicalTrials.gov
SARC005: Adjuvant Treatment of High Risk Uterine Leiomyosarcoma with Gemcitabine/Docetaxel followed by Doxorubicin: Phase II Trial
PI: Martee L Hensley, MD
Date Initiated: 1/28/2006
SARC005 on www.ClinicalTrials.gov
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumor
PI: Brigitte Widemann, MD
Date Initiated: 12/1/2005
SARC006 on www.ClinicalTrials.gov
SARC009: A Phase II Trial of Dasatinib in Advanced Sarcoma
PI: Scott Schuetze, MD, PhD
Date Initiated: 5/11/2007
SARC009 on www.ClinicalTrials.gov
SARC011: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing's sarcoma, Osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas
PI: Alberto Pappo, MD and Gilles Vassal, MD (France)
SARC011 on www.ClinicalTrials.gov
SARC012: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
PI: Lee J Helman, MD
Date Initiated:
SARC012 on www.ClinicalTrials.gov